vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Xos, Inc. (XOS). Click either name above to swap in a different company.

Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $5.2M, roughly 1.6× Xos, Inc.). Xos, Inc. runs the higher net margin — -186.8% vs -766.0%, a 579.2% gap on every dollar of revenue. On growth, Xos, Inc. posted the faster year-over-year revenue change (-54.5% vs -79.3%). Over the past eight quarters, Arcellx, Inc.'s revenue compounded faster (-24.6% CAGR vs -35.7%).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

Xos, Inc. is an American manufacturer of commercial electric vehicles (EVs) and mobile EV chargers.

ACLX vs XOS — Head-to-Head

Bigger by revenue
ACLX
ACLX
1.6× larger
ACLX
$8.1M
$5.2M
XOS
Growing faster (revenue YoY)
XOS
XOS
+24.8% gap
XOS
-54.5%
-79.3%
ACLX
Higher net margin
XOS
XOS
579.2% more per $
XOS
-186.8%
-766.0%
ACLX
Faster 2-yr revenue CAGR
ACLX
ACLX
Annualised
ACLX
-24.6%
-35.7%
XOS

Income Statement — Q1 FY2025 vs Q4 FY2025

Metric
ACLX
ACLX
XOS
XOS
Revenue
$8.1M
$5.2M
Net Profit
$-62.3M
$-9.8M
Gross Margin
-50.5%
Operating Margin
-847.6%
-186.6%
Net Margin
-766.0%
-186.8%
Revenue YoY
-79.3%
-54.5%
Net Profit YoY
-765.1%
48.6%
EPS (diluted)
$-1.13
$-0.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
XOS
XOS
Q4 25
$5.2M
Q3 25
$16.5M
Q2 25
$18.4M
Q1 25
$8.1M
$5.9M
Q4 24
$15.3M
$11.5M
Q3 24
$26.0M
$15.8M
Q2 24
$27.4M
$15.5M
Q1 24
$39.3M
$12.6M
Net Profit
ACLX
ACLX
XOS
XOS
Q4 25
$-9.8M
Q3 25
$2.1M
Q2 25
$-7.5M
Q1 25
$-62.3M
$-10.2M
Q4 24
$-47.1M
$-19.0M
Q3 24
$-25.9M
$-10.5M
Q2 24
$-27.2M
$-9.7M
Q1 24
$-7.2M
$-11.0M
Gross Margin
ACLX
ACLX
XOS
XOS
Q4 25
-50.5%
Q3 25
15.3%
Q2 25
8.8%
Q1 25
20.6%
Q4 24
-32.4%
Q3 24
18.1%
Q2 24
13.1%
Q1 24
22.1%
Operating Margin
ACLX
ACLX
XOS
XOS
Q4 25
-186.6%
Q3 25
-42.4%
Q2 25
-38.5%
Q1 25
-847.6%
-157.7%
Q4 24
-348.2%
-127.0%
Q3 24
-129.1%
-61.4%
Q2 24
-127.8%
-73.2%
Q1 24
-40.3%
-81.1%
Net Margin
ACLX
ACLX
XOS
XOS
Q4 25
-186.8%
Q3 25
12.9%
Q2 25
-40.8%
Q1 25
-766.0%
-173.3%
Q4 24
-308.4%
-165.4%
Q3 24
-99.4%
-66.6%
Q2 24
-99.3%
-62.2%
Q1 24
-18.3%
-87.1%
EPS (diluted)
ACLX
ACLX
XOS
XOS
Q4 25
$-0.76
Q3 25
$0.22
Q2 25
$-0.91
Q1 25
$-1.13
$-1.26
Q4 24
$-0.87
$-2.34
Q3 24
$-0.48
$-1.32
Q2 24
$-0.51
$-1.23
Q1 24
$-0.14
$-1.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
XOS
XOS
Cash + ST InvestmentsLiquidity on hand
$543.3M
$14.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$416.9M
$23.3M
Total Assets
$648.1M
$60.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
XOS
XOS
Q4 25
$14.0M
Q3 25
$14.1M
Q2 25
$8.8M
Q1 25
$543.3M
$4.8M
Q4 24
$587.4M
$11.0M
Q3 24
$574.3M
$8.4M
Q2 24
$516.7M
$19.7M
Q1 24
$573.9M
$46.2M
Stockholders' Equity
ACLX
ACLX
XOS
XOS
Q4 25
$23.3M
Q3 25
$31.1M
Q2 25
$18.3M
Q1 25
$416.9M
$24.8M
Q4 24
$454.8M
$33.6M
Q3 24
$483.0M
$50.8M
Q2 24
$487.2M
$59.2M
Q1 24
$496.6M
$67.8M
Total Assets
ACLX
ACLX
XOS
XOS
Q4 25
$60.4M
Q3 25
$73.8M
Q2 25
$80.3M
Q1 25
$648.1M
$87.7M
Q4 24
$711.3M
$98.3M
Q3 24
$764.9M
$120.5M
Q2 24
$734.3M
$123.4M
Q1 24
$779.7M
$135.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
XOS
XOS
Operating Cash FlowLast quarter
$-63.1M
$2.4M
Free Cash FlowOCF − Capex
$-63.9M
FCF MarginFCF / Revenue
-786.4%
Capex IntensityCapex / Revenue
9.6%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-122.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
XOS
XOS
Q4 25
$2.4M
Q3 25
$3.1M
Q2 25
$4.6M
Q1 25
$-63.1M
$-4.8M
Q4 24
$-46.0M
$3.3M
Q3 24
$30.7M
$-11.5M
Q2 24
$-36.2M
$-26.0M
Q1 24
$-31.9M
$-14.6M
Free Cash Flow
ACLX
ACLX
XOS
XOS
Q4 25
Q3 25
Q2 25
Q1 25
$-63.9M
Q4 24
$-47.5M
Q3 24
$28.4M
$-11.7M
Q2 24
$-39.5M
$-26.1M
Q1 24
$-38.3M
$-14.6M
FCF Margin
ACLX
ACLX
XOS
XOS
Q4 25
Q3 25
Q2 25
Q1 25
-786.4%
Q4 24
-311.3%
Q3 24
109.2%
-73.9%
Q2 24
-144.1%
-168.1%
Q1 24
-97.7%
-115.7%
Capex Intensity
ACLX
ACLX
XOS
XOS
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
9.6%
0.0%
Q4 24
9.8%
0.0%
Q3 24
8.8%
0.9%
Q2 24
11.7%
0.8%
Q1 24
16.4%
0.2%
Cash Conversion
ACLX
ACLX
XOS
XOS
Q4 25
Q3 25
1.45×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons